                         SEQUENCE LISTING

<110>  CNRS et al.
 
<120>  Methods and kits for predicting the sensitivity of a subject 
       suffering of renal cancer to cancer treatment

<130>  B2222PC00

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  114
<212>  PRT
<213>  Homo sapiens

<400>  1

Met Ser Leu Leu Ser Ser Arg Ala Ala Arg Val Pro Gly Pro Ser Ser 
1               5                   10                  15      


Ser Leu Cys Ala Leu Leu Val Leu Leu Leu Leu Leu Thr Gln Pro Gly 
            20                  25                  30          


Pro Ile Ala Ser Ala Gly Pro Ala Ala Ala Val Leu Arg Glu Leu Arg 
        35                  40                  45              


Cys Val Cys Leu Gln Thr Thr Gln Gly Val His Pro Lys Met Ile Ser 
    50                  55                  60                  


Asn Leu Gln Val Phe Ala Ile Gly Pro Gln Cys Ser Lys Val Glu Val 
65                  70                  75                  80  


Val Ala Ser Leu Lys Asn Gly Lys Glu Ile Cys Leu Asp Pro Glu Ala 
                85                  90                  95      


Pro Phe Leu Lys Lys Val Ile Gln Lys Ile Leu Asp Gly Gly Asn Lys 
            100                 105                 110         


Glu Asn 
        


<210>  2
<211>  1307
<212>  DNA
<213>  Homo sapiens

<400>  2
acttatctgc agacttgtag gcagcaactc accctcactc agaggtcttc tggttctgga       60

aacaactcta gctcagcctt ctccaccatg agcctcagac ttgataccac cccttcctgt      120

aacagtgcga gaccacttca tgccttgcag gtgctgctgc ttctgtcatt gctgctgact      180

gctctggctt cctccaccaa aggacaaact aagagaaact tggcgaaagg caaagaggaa      240

agtctagaca gtgacttgta tgctgaactc cgctgcatgt gtataaagac aacctctgga      300

attcatccca aaaacatcca aagtttggaa gtgatcggga aaggaaccca ttgcaaccaa      360

gtcgaagtga tagccacact gaaggatggg aggaaaatct gcctggaccc agatgctccc      420

agaatcaaga aaattgtaca gaaaaaattg gcaggtgatg aatctgctga ttaatttgtt      480

ctgtttctgc caaacttctt taactcccag gaagggtaga attttgaaac cttgattttc      540

tagagttctc atttattcag gatacctatt cttactgtat taaaatttgg atatgtgttt      600

cattctgtct caaaaatcac attttattct gagaaggttg gttaaaagat ggcagaaaga      660

agatgaaaat aaataagcct ggtttcaacc ctctaattct tgcctaaaca ttggactgta      720

ctttgcattt ttttctttaa aaatttctat tctaacacaa cttggttgat ttttcctggt      780

ctactttatg gttattagac atactcatgg gtattattag atttcataat ggtcaatgat      840

aataggaatt acatggagcc caacagagaa tatttgctca atacattttt gttaatatat      900

ttaggaactt aatggagtct ctcagtgtct tagtcctagg atgtcttatt taaaatactc      960

cctgaaagtt tattctgatg tttattttag ccatcaaaca ctaaaataat aaattggtga     1020

atatgaatct tataaactgt ggttagctgg tttaaagtga atatatttgc cactagtaga     1080

acaaaaatag atgatgaaaa tgaattaaca tatctacata gttataattc tatcattaga     1140

atgagcctta taaataagta caatatagga cttcaacctt actagactcc taattctaaa     1200

ttctactttt ttcatcaaca gaactttcat tcatttttta aaccctaaaa cttataccca     1260

cactattctt acaaaaatat tcacatgaaa taaaaatttg ctattga                   1307


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR1 (LC-CDR1) - hybridoma 35B11-8

<400>  3

Gln Ala Ser Gln Asn Ile Asn Lys Tyr Ile Ala 
1               5                   10      


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR2 (LC-CDR2) - hybridoma 35B11-8

<400>  4

Thr Ser Thr Leu Val Ser 
1               5       


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR3 (LC-CDR3) - hybridoma 35B11-8

<400>  5

Leu Gln Tyr Asp Asn Ser Pro Phe Pro 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR1 (HC-CDR1) - hybridoma 35B11-8

<400>  6

Gly Phe Thr Phe Asn Asn Tyr Trp Met 
1               5                   


<210>  7
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR2 ( HC-CDR2) - hybridoma 35B11-8

<400>  7

Ser Ile Ser Lys Thr Gly Ser Asn Pro Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  8
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR3 (HC-CDR3) - hybridoma 35B11-8

<400>  8

Asp Gly Thr Thr Pro Leu Asp Tyr Trp Gly Gln Gly Val Met 
1               5                   10                  


<210>  9
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR1 (LC-CDR1) - hybridoma 12A10-13

<400>  9

Arg Ala Ser Ser Ser Val Ser Tyr Met His 
1               5                   10  


<210>  10
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR2 (LC-CDR2) - hybridoma 12A10-13

<400>  10

Thr Ser Lys Leu Ala Ser 
1               5       


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain CDR3 (LC-CDR3) - hybridoma 12A10-13

<400>  11

Gln Gln Trp Ser Ser Asn Ser Leu Thr 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR1 (HC-CDR1) - hybridoma 12A10-13

<400>  12

Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile 
1               5                   


<210>  13
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR2 ( HC-CDR2) - hybridoma 12A10-13

<400>  13

Tyr Ile Asn Thr Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  14
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain CDR3 (HC-CDR3) - hybridoma 12A10-13

<400>  14

Pro Ser Gly Gly Phe Asp Tyr Trp Gly Gln Gly Val Met 
1               5                   10              


